We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Anesthesia and Circulating Tumor Cells in Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02005770
Recruitment Status : Recruiting
First Posted : December 9, 2013
Last Update Posted : June 20, 2016
Information provided by (Responsible Party):

Study Description
Brief Summary:
Serious concern about the role of anesthesia in tumor recurrence has considerably risen over years, but the lack of surrogate markers for tumor spreading made trials addressing this issue difficult to realize. In breast cancer patients CTC positivity has been recently recognized as an independent prognostic factor. In this respect, we postulated that in a first step changes in the number of CTC after general anesthesia would help to determine the effect of anesthesia on this tumor marker.

Condition or disease Intervention/treatment Phase
Female Breast Carcinoma Drug: Sevoflurane Drug: Propofol Phase 4

Detailed Description:
Patients with primary breast cancer will be randomized to either propofol or sevoflurane anesthesia for curative surgery. CTC will be determined in the pre- as well as postoperative phase and the kinetic of CTC in the two groups will be compared.

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 231 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Does Anesthesia Technique Affect the Presence of Circulating Tumor Cells in Primary Breast Carcinoma? A Randomised Controlled Trial.
Study Start Date : March 2014
Estimated Primary Completion Date : August 2017
Estimated Study Completion Date : August 2017

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Sevoflurane
General anesthesia using Sevoflurane
Drug: Sevoflurane
Active Comparator: Propofol
General anesthesia using propofol TCI
Drug: Propofol

Outcome Measures

Primary Outcome Measures :
  1. Number of CTC before and after administration of anesthetics [ Time Frame: 5 days ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion criteria: > Female

  • Age 18 to 85
  • Primary breast cancer (TNM stage = T1-3, N0-2, M0)
  • Primary surgery
  • Written informed consent

Exclusion criteria:

  • Metastatic breast cancer
  • Other than primary surgery (recurrence, reconstruction)
  • Pre-operative chemotherapy or radiotherapy
  • Auto-immune disease, HIV, other active cancer, age>85, ASA IV or V
  • Concomitant regional anesthesia
  • Chronic opioids medication
  • Any systemic immunosuppressive therapy
  • Known hypersensitivity or suspected allergy to propofol, soya or egg proteins
  • Known hypersensitivity to volatile anesthetics (malignant hyperthermia)
  • Pregnancy
  • Breast feeding
  • Non German-speaking patients
  • Enrollment in any other clinical trial during the course of this trial, 30 days prior to its beginning or 30 days after its completion
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02005770

Contact: Beatrice Beck Schimmer, Prof MD beatrice.beck@usz.ch
Contact: Martin Schläpfer, MD martin.schlaepfer@usz.ch

University Hospital Zurich, Institute of Anesthesiology Recruiting
Zurich, ZH, Switzerland, CH-8091
Contact: Beatrice Beck-Schimmer, Prof MD       beatrice.beck@usz.ch   
Sub-Investigator: Frédérique Hovaguimian, MD         
Institute of Physicians for Anesthesia and Intensive Care Klinik Hirslanden Recruiting
Zurich, Switzerland, 8032
Contact: Manfred Seeberger, Prof MD       manfred.seeberger@hirslanden.ch   
Contact: Rölli Urs, MD       urs.roelli@hirslanden.ch   
Sponsors and Collaborators
University of Zurich
Principal Investigator: Beatrice Beck Schimmer, Prof MD University Hospital Zurich, Institute of Anesthesiology
More Information

Responsible Party: University of Zurich
ClinicalTrials.gov Identifier: NCT02005770     History of Changes
Other Study ID Numbers: 2013-0408
First Posted: December 9, 2013    Key Record Dates
Last Update Posted: June 20, 2016
Last Verified: June 2016

Additional relevant MeSH terms:
Breast Neoplasms
Neoplastic Cells, Circulating
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms by Site
Breast Diseases
Skin Diseases
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes
Central Nervous System Depressants
Physiological Effects of Drugs
Hypnotics and Sedatives
Anesthetics, Intravenous
Anesthetics, General
Platelet Aggregation Inhibitors
Anesthetics, Inhalation